Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarendra Pegu

Showing results (21-30 of 89) with videos related to

Pageof 9
Sort By:
Nature Communications|February 15, 2019
Improvement of antibody functionality by structure-guided paratope engraftmentQingbo Liu, Yen-Ting Lai, Peng Zhang, et al.
Plos Pathogens|February 18, 2021
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruptionDenise C Hsu, Alexandra Schuetz, Rawiwan Imerbsin, et al.
Mabs|July 30, 2021
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and preventionYoung D Kwon, Mangaiarkarasi Asokan, Jason Gorman, et al.
Journal of Virology|March 20, 2015
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus InfectionKevin O Saunders, Amarendra Pegu, Ivelin S Georgiev, et al.
Journal of Virology|May 26, 2017
Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus MonkeysBoris Julg, Amarendra Pegu, Peter Abbink, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infectionAbigail Vanderheiden, Jeronay Thomas, Allison L Soung, et al.
Mbio|April 14, 2022
Erratum for Vanderheiden et al., "CCR2 Signaling Restricts SARS-CoV-2 Infection"Abigail Vanderheiden, Jeronay Thomas, Allison L Soung, et al.
Nature Communications|October 21, 2015
Activation and lysis of human CD4 cells latently infected with HIV-1Amarendra Pegu, Mangaiarkarasi Asokan, Lan Wu, et al.
Mabs|June 22, 2023
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domainYoung D Kwon, Amarendra Pegu, Eun Sung Yang, et al.
Mabs|October 30, 2020
Removal of variable domain <i>N</i>-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodiesGwo-Yu Chuang, Mangaiarkarasi Asokan, Vera B Ivleva, et al.
Pageof 9

Showing results (21-30 of 89) with videos related to

Sort By:
Pageof 9
Nature Communications|February 15, 2019
Improvement of antibody functionality by structure-guided paratope engraftmentQingbo Liu, Yen-Ting Lai, Peng Zhang, et al.
Plos Pathogens|February 18, 2021
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruptionDenise C Hsu, Alexandra Schuetz, Rawiwan Imerbsin, et al.
Mabs|July 30, 2021
A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and preventionYoung D Kwon, Mangaiarkarasi Asokan, Jason Gorman, et al.
Journal of Virology|March 20, 2015
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus InfectionKevin O Saunders, Amarendra Pegu, Ivelin S Georgiev, et al.
Journal of Virology|May 26, 2017
Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus MonkeysBoris Julg, Amarendra Pegu, Peter Abbink, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
CCR2-dependent monocyte-derived cells restrict SARS-CoV-2 infectionAbigail Vanderheiden, Jeronay Thomas, Allison L Soung, et al.
Mbio|April 14, 2022
Erratum for Vanderheiden et al., "CCR2 Signaling Restricts SARS-CoV-2 Infection"Abigail Vanderheiden, Jeronay Thomas, Allison L Soung, et al.
Nature Communications|October 21, 2015
Activation and lysis of human CD4 cells latently infected with HIV-1Amarendra Pegu, Mangaiarkarasi Asokan, Lan Wu, et al.
Mabs|June 22, 2023
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domainYoung D Kwon, Amarendra Pegu, Eun Sung Yang, et al.
Mabs|October 30, 2020
Removal of variable domain <i>N</i>-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodiesGwo-Yu Chuang, Mangaiarkarasi Asokan, Vera B Ivleva, et al.
Pageof 9